- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
International Journal of Endocrinology
Volume 2012 (2012), Article ID 519467, 6 pages
Suppression of Aldosterone Synthesis and Secretion by Channel Antagonists
1Department of Molecular Cell Biology, Institute of DNA Medicine, Research Center for Medical Sciences,
The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo 105-8461, Japan
2Division of Diabetes and Endocrinology, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo 105-8461, Japan
Received 27 July 2012; Accepted 17 September 2012
Academic Editor: Morag Young
Copyright © 2012 Keiichi Ikeda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- V. Gerc and M. Buksa, “Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases,” Medicinski Arhiv, vol. 64, no. 5, pp. 295–299, 2010.
- P. Verdecchia, G. Gentile, F. Angeli, and G. Reboldi, “Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers,” Therapeutic Advances in Cardiovascular Disease, vol. 6, no. 2, pp. 81–91, 2012.
- B. Pitt, F. Zannad, W. J. Remme et al., “The effect of spironolactone on morbidity and mortality in patients with severe heart failure,” The New England Journal of Medicine, vol. 341, no. 10, pp. 709–717, 1999.
- B. Pitt, W. Remme, F. Zannad et al., “Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction,” The New England Journal of Medicine, vol. 348, no. 14, pp. 1309–1321, 2003.
- B. Pitt, N. Reichek, R. Willenbrock et al., “Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study,” Circulation, vol. 108, no. 15, pp. 1831–1838, 2003.
- F. Zannad, J. J. V. McMurray, H. Krum et al., “Eplerenone in patients with systolic heart failure and mild symptoms,” The New England Journal of Medicine, vol. 364, no. 1, pp. 11–21, 2011.
- C. Manrique, G. Lastra, M. Gardner, and J. R. Sowers, “The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress,” Medical Clinics of North America, vol. 93, no. 3, pp. 569–582, 2009.
- A. Sato and T. Saruta, “Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy,” American Journal of Hypertension, vol. 16, no. 9, pp. 781–788, 2003.
- G. P. Rossi, “Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?” Current Hypertension Reports, vol. 8, no. 3, pp. 262–268, 2006.
- D. A. Sica, “The risks and benefits of therapy with aldosterone receptor antagonist therapy,” Current Drug Safety, vol. 2, no. 1, pp. 71–77, 2007.
- R. Sarzani, F. Guerra, L. Mancinelli, A. Buglioni, E. Franchi, and P. Dessi-Fulgheri, “Plasma Aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment,” American Journal of Hypertension, vol. 25, no. 7, pp. 818–826, 2012.
- W. Miller, “Steroidogenic enzymes,” Endocrine Development, vol. 13, pp. 1–18, 2008.
- W. L. Miller and R. J. Auchus, “The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders,” Endocrine Reviews, vol. 32, no. 1, pp. 81–151, 2011.
- A. M. Moustafa and S. B. Koritz, “Studies on the stimulation by Ca2+ and the inhibition by ADP of steroid 11β-hydroxylation in adrenal mitochondria,” European Journal of Biochemistry, vol. 78, no. 1, pp. 231–238, 1977.
- V. Pezzi, C. D. Clyne, S. Ando, J. M. Mathis, and W. E. Rainey, “Ca2+-regulated expression of aldosterone synthase is mediated by calmodulin and calmodulin-dependent protein kinases,” Endocrinology, vol. 138, no. 2, pp. 835–838, 1997.
- M. F. Rossier, M. M. Burnay, M. B. Vallotton, and A. M. Capponi, “Distinct functions of T- and L-type calcium channels during activation of bovine adrenal glomerulosa cells,” Endocrinology, vol. 137, no. 11, pp. 4817–4826, 1996.
- X. L. Chen, D. A. Bayliss, R. J. Fern, and P. Q. Barrett, “A role for T-type Ca2+ channels in the synergistic control of aldosterone production by ANG II and K+,” American Journal of Physiology, vol. 276, no. 5, pp. F674–F683, 1999.
- K. Imagawa, S. Okayama, M. Takaoka et al., “Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells,” Journal of Cardiovascular Pharmacology, vol. 47, no. 1, pp. 133–138, 2006.
- O. Akizuki, A. Inayoshi, T. Kitayama et al., “Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R,” European Journal of Pharmacology, vol. 584, no. 2-3, pp. 424–434, 2008.
- T. Isaka, K. Ikeda, Y. Takada, Y. Inada, K. Tojo, and N. Tajima, “Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R,” European Journal of Pharmacology, vol. 605, no. 1–3, pp. 49–52, 2009.
- A. K. Pandey, W. Li, X. Yin, D. M. Stocco, P. Grammas, and X. Wang, “Blocking L-type calcium channels reduced the threshold of cAMP-induced steroidogenic acute regulatory gene expression in MA-10 mouse Leydig cells,” Journal of Endocrinology, vol. 204, no. 1, pp. 67–74, 2010.
- K. Ikeda, T. Saito, and K. Tojo, “Efonidipine, a Ca2+-channel blocker, enhances the production of dehydroepiandrosterone sulfate in NCI-H295R human adrenocortical carcinoma cells,” Tohoku Journal of Experimental Medicine, vol. 224, no. 4, pp. 263–271, 2011.
- S. Aritomi, H. Wagatsuma, T. Numata et al., “Expression of N-type calcium channels in human adrenocortical cells and their contribution to corticosteroid synthesis,” Hypertension Research, vol. 34, no. 2, pp. 193–201, 2011.
- T. Furukawa, T. Nukada, Y. Namiki et al., “Five different profiles of dihydropyridines in blocking T-type Ca2+ channel subtypes (Cav3.1 (α1G), Cav3.2 (α1H), and Cav3.3 (α1I)) expressed in Xenopus oocytes,” European Journal of Pharmacology, vol. 613, no. 1–3, pp. 100–107, 2009.
- E. Perez-Reyes, A. L. Van Deusen, and I. Vitko, “Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs,” Journal of Pharmacology and Experimental Therapeutics, vol. 328, no. 2, pp. 621–627, 2009.
- C. P. Python, O. P. Laban, M. F. Rossier, M. B. Vallotton, and A. M. Capponi, “The site of action of Ca2+ in the activation of steroidogenesis: studies in Ca2+-clamped bovine adrenal zona-glomerulosa cells,” Biochemical Journal, vol. 305, no. 2, pp. 569–576, 1995.
- I. M. Bird, R. A. Word, C. Clyne, J. I. Mason, and W. E. Rainey, “Potassium negatively regulates angiotensin II type 1 receptor expression in human adrenocortical H295R cells,” Hypertension, vol. 25, no. 6, pp. 1129–1134, 1995.
- N. Gallo-Payet, E. Grazzini, M. Côté et al., “Role of Ca2+ in the action of adrenocorticotropin in cultured human adrenal glomerulosa cells,” Journal of Clinical Investigation, vol. 98, no. 2, pp. 460–466, 1996.
- V. N. Uebele, C. E. Nuss, J. J. Renger, and T. M. Connolly, “Role of voltage-gated calcium channels in potassium-stimulated aldosterone secretion from rat adrenal zona glomerulosa cells,” Journal of Steroid Biochemistry and Molecular Biology, vol. 92, no. 3, pp. 209–218, 2004.
- M. F. Rossier, C. P. Python, A. M. Capponi, W. Schlegel, C. Y. Kwan, and M. B. Vallotton, “Blocking T-type calcium channels with tetrandrine inhibits steroidogenesis in bovine adrenal glomerulosa cells,” Endocrinology, vol. 132, no. 3, pp. 1035–1043, 1993.
- M. F. Rossier, E. A. Ertel, M. B. Vallotton, and A. M. Capponi, “Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 287, no. 3, pp. 824–831, 1998.
- D. P. Lotshaw, “Role of membrane depolarization and T-type Ca2+ channels in angiotensin II and K+ stimulated aldosterone secretion,” Molecular and Cellular Endocrinology, vol. 175, no. 1-2, pp. 157–171, 2001.
- H. Masumiya, T. Shijuku, H. Tanaka, and K. Shigenobu, “Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect,” European Journal of Pharmacology, vol. 349, no. 2-3, pp. 351–357, 1998.
- H. Uneyama, H. Uchida, T. Konda, R. Yoshimoto, and N. Akaike, “Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels,” European Journal of Pharmacology, vol. 373, no. 1, pp. 93–100, 1999.
- E. Yamamoto, K. Kataoka, Y. F. Dong et al., “Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats,” Journal of Hypertension, vol. 28, no. 6, pp. 1321–1329, 2010.
- K. Ohtani, S. Usui, S. Kaneko, et al., “Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in mice,” Hypertension Research, vol. 35, no. 3, pp. 287–294, 2012.
- S. Aritomi, T. Konda, and M. Yoshimura, “L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action,” Heart Vessels, vol. 27, no. 4, pp. 419–423, 2011.
- T. Isaka, N. Sakamoto, T. Hayashi, K. Ikeda, M. Sakamoto, and K. Tojo, “Azelnidipine decreased plasma aldosterone and plasminogen activator inhibitor type 1 levels in the hypertensive patients with type 2 diabetes mellitus—the Jikei Azelnidipine study in the patients with hypertension and diabetes mellitus (JAz-HDM),” Therapeutic Research, vol. 32, no. 3, pp. 371–381, 2011.
- M. Abe, K. Okada, N. Maruyama et al., “Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria,” Hypertension Research, vol. 34, no. 2, pp. 268–273, 2011.
- T. Ishimitsu, T. Kameda, A. Akashiba et al., “Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis,” Hypertension Research, vol. 30, no. 7, pp. 621–626, 2007.
- T. Tsutamoto, T. Tanaka, K. Nishiyama et al., “Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension,” Hypertension Research, vol. 32, no. 8, pp. 670–674, 2009.
- A. Nguyen Dinh Cat and F. Jaisser, “Extrarenal effects of aldosterone,” Current Opinion in Nephrology and Hypertension, vol. 21, no. 2, pp. 147–156, 2012.
- A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003.
- G. Mancia, G. De Backer, A. Dominiczak et al., “2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC),” Journal of Hypertension, vol. 25, no. 6, pp. 1105–1187, 2007.
- T. Ogihara, K. Kikuchi, H. Matsuoka et al., “The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009),” Hypertension Research, vol. 32, no. 1, pp. 3–107, 2009.
- J. G. Wang, K. Kario, T. Lau et al., “Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association,” Hypertension Research, vol. 34, no. 4, pp. 423–430, 2011.
- D. M. Rabi, S. S. Daskalopoulou, R. S. Padwal, et al., “The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy,” Canadian Journal of Cardiology, vol. 27, no. 4, pp. 415–433, 2011.
- K. K. Gaddam and S. Oparil, “Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy,” Journal of the American Society of Hypertension, vol. 3, no. 1, pp. 52–68, 2009.
- K. Kario, “Proposal of RAS-diuretic vs. RAS-calcium antagonist strategies in high-risk hypertension: insight from the 24-hour ambulatory blood pressure profile and central pressure,” Journal of the American Society of Hypertension, vol. 4, no. 5, pp. 215–218, 2010.
- J. J. Mourad, S. Le Jeune, A. Pirollo, C. Mourad, Y. Gaudouen, and M. Lopez-Sublet, “Combinations of inhibitors of the reninangiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine,” Current Medical Research and Opinion, vol. 26, no. 9, pp. 2263–2276, 2010.
- S. Nagahama, T. Norimatsu, T. Maki, M. Yasuda, and S. Tanaka, “The effect of combination therapy with an L/N-type Ca2+ channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan,” Hypertension Research, vol. 30, no. 9, pp. 815–822, 2007.
- S. Katayama, R. Kawamori, Y. Iwamoto, I. Saito, and K. Kuramoto, “In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study,” Hypertension Research, vol. 31, no. 8, pp. 1499–1508, 2008.
- T. Ogihara, T. Saruta, K. Shimada, and K. Kuramoto, “A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: The REZALT study,” Hypertension Research, vol. 32, no. 12, pp. 1148–1154, 2009.
- M. Matsuzaki, T. Ogihara, S. Umemoto et al., “Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial,” Journal of Hypertension, vol. 29, no. 8, pp. 1649–1659, 2011.
- D. A. Sica, “Endocrine causes of secondary hypertension,” Journal of Clinical Hypertension, vol. 10, no. 7, pp. 534–540, 2008.
- J. D. Dietz, S. Du, C. W. Bolten et al., “A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity,” Hypertension, vol. 51, no. 3, pp. 742–748, 2008.
- H. Kosaka, K. Hirayama, N. Yoda et al., “The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family,” European Journal of Pharmacology, vol. 635, no. 1–3, pp. 49–55, 2010.